Proquazone ('Biarison') in osteoarthritis of the knee: a double-blind, dose comparison trial.
A double-blind study was carried out in 36 patients with osteoarthritis to evaluate the effectiveness and tolerance of 600 mg proquazone per day compared with 900 mg proquazone per day over a period of 3 months. The two groups showed statistically significant improvement in all the parameters investigated, thus confirming the potency of proquazone as an analgesic anti-inflammatory drug. The difference between the 2 groups, however, was not statistically significant, indicating an advantage for the lower daily dosage regimen over the high daily dosage regimen. Side-effects were more frequent and more severe in the high daily dosage group, demonstrating a further advantage of the lower daily dosage regimen.
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007719:Knee Joint; D008297:Male; D008875:Middle Aged; D010003:Osteoarthritis / Q000188:drug therapy*; D011799:Quinazolines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013272:Stomach Diseases / Q000139:chemically induced
D000893:Anti-Inflammatory Agents; D011799:Quinazolines; C011385:proquazone